加拿大活跃巨细胞动脉炎患者的治疗模式和临床结果
Jean-Paul Makhzoum1, Miriam Avadisian2, Dalinda Liazoghli2
1Hôpital du Sacré-Coeur de Montréal, Université de Montréal, 5400 Boul Gouin O, Montréal, Québec, H4J 1C5, Canada. jean-paul.makhzoum@umontreal.ca.
Rheumatology and therapy
|December 24, 2025
概括
用托西利祖马布 (TCZ) 治疗巨细胞动脉炎 (GCA) 的缓解率与单独使用葡萄糖皮质类药物相似,但与较低的类固醇暴露. 然而,目前的1年TCZ限制可能不足以持续控制GCA.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 血管炎研究 血管炎研究
背景情况:
- 巨细胞动脉炎 (GCA) 是一种需要长期治疗的大血管血管炎.
- 葡萄糖皮质类药物 (GCs) 是标准的,但会引起显著的不良影响.
- 托西利祖马布 (TCZ) 是一种IL-6抑制剂,提供一种GC节约的替代品,但最佳持续时间尚不清楚.
研究的目的:
- 评估GCA患者的治疗模式,临床结果和GC负担.
- 为了比较GC单疗法,GC+TCZ和GC+其他免疫抑制剂 (OIS).
- 评估持续缓解率和12个月后的GC暴露.
主要方法:
- 121名GCA患者的回顾性队列研究 (2017年1月至2025年2月).
- 根据初始处理进行分层:仅GC,GC+TCZ,GC+OIS.
- 主要终点:在12个月持续缓解 (症状和炎症标志物≥6个月).
主要成果:
- 在68.6%的患者中实现了持续缓解;仅GC (72.9%) 和GC+TCZ (69.8%) 的比率相似,但GC+OIS (40.0%) 的比率较低.
- 近一半的患者 (47.9%) 复发;第一次复发的中位时间为283.5天.
- TCZ组的累积GC暴露量 (3431毫克) 与仅GC (4690毫克) 相比较低,尽管TCZ停止后25.4%的复发.
结论:
- 加拿大的1年TCZ治疗限制可能不足以长期控制GCA.
- 需要个性化,长期的策略,以尽量减少类固醇暴露,并保持疾病缓解.
- 对最佳的TCZ持续时间和对类固醇节约剂的政策变化的进一步研究是有必要的.
相关概念视频
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


